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On June 12, 2013, the Thailand Ministry of Health and 
CDC published results from a randomized controlled trial of 
a daily oral dose of 300 mg of tenofovir disoproxil fumarate 
(TDF) that showed efficacy in reducing the acquisition of 
human immunodeficiency virus (HIV) infection among inject-
ing drug users (IDUs) (1). Based on these findings, CDC rec-
ommends that preexposure prophylaxis (PrEP) be considered 
as one of several prevention options for persons at very high 
risk for HIV acquisition through the injection of illicit drugs. 
Background 
Among the approximately 50,000 new HIV infections 
acquired each year in the United States, 8% were attributed to 
injection-drug use in 2010 (2). The National HIV Behavioral 
Surveillance System, surveying IDUs in 20 U.S. cities in 2009, 
found high frequencies of both injection-drug use and sexual 
practices that are associated with HIV acquisition (3). Among 
IDUs without HIV infection, 34% reported having shared 
syringes in the preceding 12 months, and 58% reported having 
shared injection equipment; 69% reported having unprotected 
vaginal sex and 23% reported having unprotected male-female 
anal sex. Among HIV-uninfected male IDUs, 7% reported 
previous male-male anal sex, and 5% reported unprotected 
male-male anal sex. However, only 19% of male and female 
IDUs reported participating in an intervention to reduce risk 
behaviors. These findings underscore a need to provide effective 
interventions to further reduce HIV infections among IDUs 
in the United States. 
Several clinical trials have demonstrated safety and efficacy 
of daily oral antiretroviral PrEP for the prevention of HIV 
acquisition among men who have sex with men (MSM) (4) and 
heterosexually active men and women (5,6), although two trials 
were unable to show efficacy, likely because of low adherence 
(7,8) (Table). CDC previously has issued interim guidance for 
PrEP use with MSM (9) and heterosexually active adults (10) 
and now provides interim guidance for PrEP use in IDUs. 
During 2009–2013, CDC convened workgroup meetings 
and consulted with external subject matter experts, includ-
ing clinicians, epidemiologists, academic researchers, health 
department policy and program staff members, community 
representatives, and HIV and substance abuse subject mat-
ter experts at federal health agencies, to 1) review the results 
of PrEP trials and other data as they became available and 
2) deliberate and recommend content for interim guidance 
and comprehensive U.S. Public Health Service guidelines for 
PrEP use in the United States. The expert opinions from the 
IDU workgroup and other workgroups were used to develop 
this interim guidance on PrEP use with IDUs. 
Rationale and Evidence 
The Bangkok Tenofovir Study enrolled HIV-uninfected per-
sons who reported injecting illicit drugs in the prior year into 
a phase-III randomized, double-blind, placebo-controlled trial 
to determine the safety and efficacy of daily oral TDF to reduce 
the risk for HIV acquisition. In all, 2,413 eligible, consenting 
men and women aged 20–60 years were randomized to receive 
either daily oral doses of 300 mg of TDF (n = 1,204) or a placebo 
tablet (n = 1,209). Participants could elect to receive tablets daily 
by directly observed therapy or receive a 28-day supply of daily 
doses to take home; they could switch medication supply method 
at their monthly follow-up visits. At follow-up visits every 
28 days, individualized adherence and risk-reduction counseling, 
HIV testing, pregnancy testing for women, and assessment for 
adverse events were conducted. An audio computer-assisted self-
interview was conducted every 3 months to assess risk behaviors. 
Blood was collected at enrollment; months 1, 2, and 3; and 
then every 3 months for laboratory testing to screen for adverse 
reactions to the medication. At study clinics (operated by the 
Bangkok Metropolitan Administration), social services, primary 
medical care, methadone, condoms, and bleach (for cleaning 
injection equipment) were provided free of charge. 
The study was conducted during 2005–2012, with a mean 
follow-up time of 4.6 years (maximum: 6.9 years) and a 24% 
loss to follow-up or voluntary withdrawal in the TDF group 
and a 23% loss in the placebo group. Participants took their 
study drug an average of 83.8% of days and were on directly 
observed therapy 86.9% of the time. 
After enrollment, 50 patients acquired HIV infection: 17 
in the TDF group and 33 in the placebo group. In the modi-
fied “intent-to-treat” analysis (excluding two participants later 
found to have been HIV-infected at enrollment), HIV inci-
dence was 0.35 per 100 person-years in the TDF group and 
0.68 per 100 person-years in the placebo group, representing a 
48.9% reduction in HIV incidence (95% confidence interval 
[CI] = 9.6%–72.2%). Among those in an unmatched case-
control study that included the 50 persons with incident HIV 
infection (case-patients) and 282 HIV-uninfected participants 
from four clinics (controls), detection of tenofovir in plasma 
was associated with a 70% reduction in the risk for HIV infec-
tion (CI = 2.3%–90.6%). 
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The rates of adverse events, serious adverse events, deaths, 
grade 3–4 laboratory abnormalities, and elevated serum cre-
atinine did not differ significantly between the two groups. 
Reports of nausea and vomiting were higher in the TDF group 
than the placebo group in the first 2 months of medication 
use but not thereafter. No HIV infections with mutations 
associated with TDF resistance were identified among 
HIV-infected participants. 
Comparing rates at enrollment with rates at 12 months of 
follow-up, risk behaviors decreased significantly for inject-
ing drugs (from 62.7% to 22.7%), sharing needles (18.1% 
to 2.3%), and reporting multiple sexual partners (21.7% to 
11.0%), and these risk behaviors remained below baseline 
throughout the entire period of the trial (all three comparisons, 
p<0.001). Rates were similar in the TDF and placebo groups. 
PrEP Recommendation for IDUs 
On July 16, 2012, based on the results of trials in MSM and 
heterosexually active women and men, the Food and Drug 
Administration approved a label indication for the use of the 
fixed dose combination of TDF 300 mg and emtricitabine 
(FTC) 200 mg (Truvada) as PrEP against sexual HIV acqui-
sition by MSM and heterosexually active women and men 
(11). These trials did not evaluate safety and efficacy among 
injecting-drug users. 
CDC recommends that daily TDF/FTC be the preferred 
PrEP regimen for IDUs for the following reasons: 1) TDF/FTC 
contains the same dose of TDF (300 mg) proven effective for 
IDUs, 2) TDF/FTC showed no additional toxicities com-
pared with TDF alone in PrEP trials that have provided both 
regimens, 3) IDUs also are at risk for sexual HIV acquisition 
for which TDF/FTC is indicated, and 4) TDF/FTC has an 
approved label indication for PrEP to prevent sexual HIV 
acquisition in the United States. Its use to prevent parenteral 
HIV acquisition in those without sexual acquisition risk is 
currently an “off-label” use. Reported injection practices that 
place persons at very high risk for HIV acquisition include 
sharing of injection equipment, injecting one or more times 
a day, and injection of cocaine or methamphetamine. CDC 
recommends that prevention services provided for IDUs receiv-
ing PrEP include those targeting both injection and sexual risk 
behaviors (12). 
In all populations, PrEP use 1) is contraindicated in persons 
with unknown or positive HIV status or with an estimated 
creatinine clearance <60 mL/min, 2) should be targeted to 
adults at very high risk for HIV acquisition, 3) should be 
delivered as part of a comprehensive set of prevention services, 
and 4) should be accompanied by quarterly monitoring of HIV 
status, pregnancy status, side effects, medication adherence, 
and risk behaviors, as outlined in previous interim guidance 
(9,10). Adherence to daily PrEP is critical to reduce the risk for 
HIV acquisition, and achieving high adherence was difficult 
for many participants in PrEP clinical trials (Table). 
Comment 
Providing PrEP to IDUs at very high risk for HIV acquisi-
tion could contribute to the reduction of HIV incidence in the 
United States. In addition, if PrEP delivery is integrated with 
prevention and clinical care for the additional health concerns 
faced by IDUs (e.g., hepatitis B and C infection, abscesses, and 
overdose), substance abuse treatment and behavioral health 
care, and social services, PrEP will contribute additional ben-
efits to a population with multiple life-threatening physical, 
mental, and social health challenges (12,13). CDC, in collabo-
ration with other federal agencies, is preparing comprehensive 
U.S. Public Health Service guidelines on the use of PrEP with 
MSM, heterosexually active men and women, and IDUs, cur-
rently scheduled for release in 2013. 
TABLE. Results from randomized, placebo-controlled, clinical trials of the efficacy of daily oral antiretroviral preexposure prophylaxis (PrEP) 






based on TDF detection in blood
% (95% CI) % (95% CI)
Bangkok Tenofovir Study Injecting drug users TDF 49 (10–72) 70 (2–91)
Partners PrEP HIV discordant couples TDF 67 (44–81) 86 (67–94)
TDF/FTC 75 (55–87) 90 (58–98)
TDF2 Heterosexually active 
men and women
TDF/FTC 62 (22–83) 84 NS
iPrEx Men who have sex with men TDF/FTC 42 (18–60) 92 (40–99)
Fem-PrEP Heterosexually active women TDF/FTC NS — NA —
VOICE Heterosexually active women TDF NS — NA —
TDF/FTC NS — NA —
Abbreviations: mITT = modified intent to treat analysis, excluding persons determined to have had HIV infection at enrollment; CI = confidence interval; TDF = tenofovir 
disoproxil fumarate; FTC = emtricitabine; NS = not statistically significant; NA = data not available.
* % reduction in acquisition of HIV infection. 
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